Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product ...
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...
England’s National Institute for Health and Care Excellence (NICE) has recommended Santhera Pharmaceuticals’ treatment for Duchenne muscular dystrophy (DMD) Agamree (vamorolone) following a ...
Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.
Pratteln, Switzerland, December 11, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that China’s National Medical Products Administration (NMPA) has approved AGAMREE® (vamorolone ...
Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE ...
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) ...